Physician profile
Saumya Kumar
NPI 1780814244
$1,784.97
in general payments reported to CMS, 2019-2025
14 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $190 · 2021: $47.98 · 2022: $194 · 2023: $523 · 2024: $191 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $507.00 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $288.21 | 2022-2023 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $172.70 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $166.59 | 2019-2024 | Zepbound, Mounjaro |
| Dexcom, INC. | $162.06 | 2019-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $161.81 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Sanofi-Aventis U.S. LLC | $100.33 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $73.90 | 2022-2024 | Gvoke Hypopen |
| Amgen INC. | $57.73 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.84 | 2022 | |
| Beta Bionics, INC. | $23.62 | 2024 | Ilet Bionic Pancreas |
| Lifescan, INC. | $16.43 | 2020 | |
| Insulet Corporation | $13.96 | 2019 | |
| Radius Health, INC. | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saumya Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.